Figure 7: The Arf6-based mesenchymal pathway in drug resistance.
From: Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer
(a,b) Silencing of AMAP1 and EPB41L5 enhances the drug sensitivity of 786-O cells. 786-O cells, pretreated with siRNA duplexes for AMAP1 or EPB41L5, or with an irrelevant sequence (Irr), were treated with Temsirolimus (a) or Sunitinib (b) at the indicated concentrations for 3 days, and numbers of viable cells were then analysed. Data are presented as ratios, by normalizing values obtained by setting the untreated cells of each siRNA treatment as 1.0. Error bars show the mean±s.e.m., n=3. *P<0.05, **P<0.01. Statistical analyses were performed using analysis of variance. (c,d) 786-O cells treated with shRNAs for EPB41L5 (shEPB41L5) or an irrelevant sequence (Irr), were subcutaneously injected into nude mice. Ten days after injection, mice were randomized into two groups, those treated with Temsirolimus (10 mg kg−1) (+Tem.) and those treated with PBS (+PBS) on a QDx5 schedule, and their tumour sizes (c) and body weights (d) were monitored for further 6 weeks, as indicated. Error bars show the mean±s.e.m., n=6. *P<0.05. Statistical analyses were performed using Student’s t-test.
